Audio: So I'm Dr. Gabriel Chiosis. I'm a professor and member at Sloan-Kettering Cancer Center and I'm going to discuss today our work or an overview first of our approach to treatment which is to target 1330 interaction networks rather than a protein or an interact or the interaction of two proteins as generally or at least historically we think about therapy, and the paper I was invited to discuss is it's a protocol we published recently our cells...Read Full Transcript Here
Gabriela Chiosis, Ph.D., Researcher at Memorial Sloan Kettering Cancer Center. In this video, she speaks a
Gabriela Chiosis, Ph.D., Researcher at Memorial Sloan Kettering Cancer Center. In this audio, she speaks about the Synthesis of 124I-labeled epichaperome probes and assessment in visualizing pathologic protein-protein interaction networks in tumor bearing mice.
Epichaperomes are pathologic scaffolding linked with disease that are made up of firmly bonded chaperones and co-chaperones. They enable precision therapy by detecting and targeting faulty protein-protein interaction networks rather than a single protein. This technique discusses the manufacture and characterization of two 124I-labeled epichaperome probes, [124I]-PU-H71 and [124I]-PU-AD, which have both been used in clinical trials. It details how to utilize these reagents to visualize and quantify epichaperome-positivity in tumor-bearing mice using positron emission tomography.